Eli Lilly inks pacts for Baricitinib with Sun Pharma, Cipla, Lupin for COVID-19 treatment in India

The company "has issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla, Lupin and Sun Pharmaceutical Industries, who are collaborating with Lilly to accelerate and expand the availability of Baricitinib in India," Eli Lilly and Company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3twC7ly
via IFTTT